HC Wainwright Raises Greenwich LifeSciences (NASDAQ:GLSI) Price Target to $39.00

Greenwich LifeSciences (NASDAQ:GLSI) had its price target boosted by analysts at HC Wainwright from $38.00 to $39.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 304.98% from the stock’s current price.

Greenwich LifeSciences Trading Up 3.1 %

GLSI opened at $9.63 on Monday. Greenwich LifeSciences has a 12 month low of $8.06 and a 12 month high of $18.75. The business’s 50-day moving average price is $10.77 and its 200-day moving average price is $12.31. The company has a market cap of $127.83 million, a P/E ratio of -12.04 and a beta of 1.76.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings results on Tuesday, April 15th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.40). Equities research analysts forecast that Greenwich LifeSciences will post -0.8 earnings per share for the current fiscal year.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel bought 3,600 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $9.10 per share, with a total value of $32,760.00. Following the completion of the purchase, the chief executive officer now directly owns 5,561,602 shares of the company’s stock, valued at $50,610,578.20. This trade represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders bought 14,500 shares of company stock worth $129,267 in the last three months. 51.67% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GLSI. State Street Corp grew its position in shares of Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after buying an additional 3,005 shares during the last quarter. Geode Capital Management LLC lifted its stake in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after acquiring an additional 5,861 shares during the period. Barclays PLC lifted its stake in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after acquiring an additional 6,538 shares during the period. Brown Brothers Harriman & Co. bought a new stake in Greenwich LifeSciences in the fourth quarter valued at $45,000. Finally, Garden State Investment Advisory Services LLC purchased a new position in Greenwich LifeSciences during the 3rd quarter valued at $253,000. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.